Подписаться на RSSОбновление для Samsung Wave уже можно скачать с помощью программы Samsung Kies, а bada 2.0 для смартфона Samsung Wave II станет доступна российским пользователям до конца мая. bada 2.0 открывает пользователям массу новых возможностей, в том числе многозадачность, обновленный интерфейс Samsung
программы для самсунга d 600
Дайджест мобильных новостей за прошедшую неделю. Новый HTC Desire C, сверхдешёвые Nokia, 3D-смартфоны от Nokia и Samsung
Реклама, анонсы, конец передачи, и рубрика 'Cериал' НТВ, зима 2006
Анонс фильма "Парни из стали" и реклама: 1 - Samsung 2 - Cillit Bang 3 - Терафлю 4 - Samsung D 800 5 - Volvo 6 - Бумер-2 7 - RTH 8 ...
Hands on: Foxtel Catch Up TV
25.05.12 - The Age (blog)
In the last 12 months Foxtel has introduced basic IPTV packages for Microsoft's Xbox 360, Telstra's T-Box and now Samsung Smart TVs. They're cheaper than a traditional Foxtel subscription, but the trade-off is you get access to less channels. The XBox
Hands on: Foxtel Catch Up TV
25.05.12 - Sydney Morning Herald (blog)
In the last 12 months Foxtel has introduced basic IPTV packages for Microsoft's Xbox 360, Telstra's T-Box and now Samsung Smart TVs. They're cheaper than a traditional Foxtel subscription, but the trade-off is you get access to less channels. The XBox
Regulus Therapeutics to Present microRNA Platform and Pipeline Updates at Two ...
25.05.12 - Sacramento Bee
/PRNewswire/ -- Regulus Therapeutics Inc ., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that data from its proprietary lead program targeting microRNA-33a/b (miR-33a/b), currently in preclinical development for the treatment of atherosclerosis, will be presented at the Keystone Symposium "Nucleic Acid Therapeutics: From Base Pairs to Bedsides" held Jan. 10–15, 2012, in Santa Fe, New Mexico. In addition, information from its preclinical oncology programs will be presented at the American Association for Cancer Research's (AACR) Noncoding RNAs and Cancer workshop held Jan. 8-11, 2012, in Miami, Florida.
"We are pleased to present data about our proprietary microRNA programs in metabolic disease and oncology at the Keystone Symposium and AACR Special Conference respectively," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus Therapeutics. "Our scientists have made significant progress discovering potent and safe therapeutic oligonucleotide anti-miRs. We look forward to selecting clinical candidates this year for the advancement of multiple microRNA therapeutic programs into the clinic."
Источник: